Logo Alfasigma
Alfasigma worldwide
  • Belgium
  • China
  • Czech Republic
  • France
  • India
  • Italy
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Russia
  • Slovak Republic
  • Spain
  • Switzerland
  • Tunisia
  • Usa
  • Belgium
  • China
  • Czech Republic
  • France
  • India
  • Italy
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Russia
  • Slovak Republic
  • Spain
  • Switzerland
  • Tunisia
  • Usa
  • Our Company
    • Alfasigma at glance
    • Our purpose
    • Cultural Values
    • Leadership model
    • Our Legacy
    • Ethics&transparency
      • HCP/HCO relationship
      • Patient associations funding
      • Code of ethics
      • Pharmacovigilance
  • Therapeutic Areas
    • All therapeutic areas
    • Gastroenterology
    • Vascular
  • Research & Innovation
  • CSR
  • Financials
  • Contract Manufacturing
  • Our People
  • News & Media
    • Newsroom
    • Media Center
  • Contacts
  • Our Company
    • Alfasigma at glance
    • Our purpose
    • Cultural Values
    • Leadership model
    • Our Legacy
    • Ethics&transparency
      • HCP/HCO relationship
      • Patient associations funding
      • Code of ethics
      • Pharmacovigilance
  • Therapeutic Areas
    • All therapeutic areas
    • Gastroenterology
    • Vascular
  • Research & Innovation
  • CSR
  • Financials
  • Contract Manufacturing
  • Our People
  • News & Media
    • Newsroom
    • Media Center
  • Contacts

Home Newsroom / Products

Sulodexide in EVF Guidelines for Prevention of Post-Thrombotic Syndrome (PTS)

June 11, 2020

New EVF Guidelines publication entitled Management of CVD of lower limbs – Part II reports Sulodexide scientific evidences in the dedicated chapter to Prevention of Post-Thrombotic Syndrome, definin...

Read more

Brilacidin, license agreement with Innovation Pharmaceuticals

July 22, 2019

Innovation Pharmaceuticals announces License Agreement with Alfasigma S.p.A. for the development and commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis....

Read more

Alfasigma USA Acquires Zelnorm™

July 8, 2019

Alfasigma USA has acquired the brand ZELNORM (tegaserod), a treatment for IBS-C, from Sloan Pharma, with the aim to relaunch the brand in the United States....

Read more

© 2020 Alfasigma S.p.A. | VAT 03432221202 | Privacy Policy | Data Subjects Rights | Cookie Policy | Legal Notice